| 臺大學術典藏 |
2022-02-22T05:34:11Z |
Liver stiffness-based score at sustained virologic response predicts liver-related complications after eradication of hepatitis C virus
|
Kuo Y.-H.; Kee K.-M.; Hung C.-H.; Lu S.-N.; Hu T.-H.; CHIEN-HUNG CHEN; Wang J.-H. |
| 臺大學術典藏 |
2022-02-22T05:34:11Z |
Chronic hepatitis B exhibited higher rate of hepatocellular carcinoma occurrence than hepatitis C in cirrhotic patients after effective antiviral treatment
|
Lin M.-T.; Chang K.-C.; Yen Y.-H.; Tsai M.-C.; CHIEN-HUNG CHEN; Wang J.-H.; Hsiao C.-C.; Chiu Y.-H.; Hu T.-H. |
| 臺大學術典藏 |
2022-02-22T05:34:11Z |
Use of glecaprevir/pibrentasvir in patients with chronic hepatitis c virus infection and severe renal impairment
|
Yap D.Y.H.; Liu K.S.H.; Hsu Y.-C.; Wong G.L.H.; Tsai M.-C.; CHIEN-HUNG CHEN; Hsu C.-S.; Hui Y.T.; Li M.K.K.; Liu C.-H.; Kan Y.-M.; Yu M.-L.; Yuen M.-F. |
| 臺大學術典藏 |
2022-02-22T05:34:12Z |
Hepatitis C virus core antigen is cost-effective in community-based screening of active hepatitis C infection in Taiwan
|
Wang J.-H.; CHIEN-HUNG CHEN; Chang C.-M.; Feng W.-C.; Lee C.-Y.; Lu S.-N. |
| 臺大學術典藏 |
2022-02-22T05:34:12Z |
Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C
|
Hsu S.-J.; Chiu M.-C.; Fang Y.-J.; Yang T.-H.; Yu J.-J.; Chen C.-C.; Kuo C.-C.; Lee J.-Y.; CHIEN-HUNG CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-02-22T05:34:12Z |
Microelimination of chronic hepatitis C by universal screening plus direct-acting antivirals for incarcerated persons in Taiwan
|
Yang T.-H.; Fang Y.-J.; Hsu S.-J.; Lee J.-Y.; Chiu M.-C.; Yu J.-J.; Kuo C.-C.; CHIEN-HUNG CHEN |
| 臺大學術典藏 |
2022-02-22T05:34:13Z |
Current efficacy and prospectives of oral direct-acting antiviral drugs to treat chronic hepatitis c
|
Lo C.-C.; Chen M.-T.; Huang K.-C.; Lin C.-H.; Cheng H.-S.; Liao Y.-T.; Hung L.-W.; Lu S.-N.; CHIEN-HUNG CHEN |
| 臺大學術典藏 |
2022-02-22T05:34:13Z |
Adoptive donor immunity protects against resolved hepatitis B virus reactivation after allogeneic haematopoietic stem cell transplantation in the world's largest retrospective cohort study
|
Liu J.-H.; Liao X.-W.; CHIEN-HUNG CHEN; Yao M.; Li C.-C.; Lin C.-T.; Tsai C.-H.; Chou W.-C.; Hou H.-A.; Huang S.-Y.; Wu S.-J.; Chen Y.-C.; Tien H.-F.; Tang J.-L.; Ko B.-S. |
| 臺大學術典藏 |
2022-02-22T05:34:13Z |
Clinical Manifestations and Outcomes of Patients with Sarcomatoid Hepatocellular Carcinoma
|
Liao S.-H.; Su T.-H.; Jeng Y.-M.; Liang P.-C.; Chen D.-S.; CHIEN-HUNG CHEN; Kao J.-H. |
| 臺大學術典藏 |
2022-02-22T05:34:14Z |
Multidisciplinary Taiwan consensus recommendations for the use of DEBDOX-TACE in hepatocellular carcinoma treatment
|
Chang P.-Y.; Huang C.-C.; Hung C.-H.; Yu C.-Y.; Wu D.-K.; Hwang J.-I.; Liang P.-C.; Wu R.-H.; Tsai W.-L.; Lin Y.-J.; Liu Y.-S.; Liang H.-L.; Lee R.-C.; CHIEN-HUNG CHEN |
| 臺大學術典藏 |
2022-02-22T05:34:14Z |
Change of Uncertainty in Illness and Unmet Care Needs in Patients with Recurrent Hepatocellular Carcinoma during Active Treatment
|
Shun S.-C.; Chou Y.-J.; CHIEN-HUNG CHEN; Yang J.-C. |
| 臺大學術典藏 |
2022-02-22T05:34:15Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; CHIEN-HUNG CHEN; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2022-02-22T05:34:15Z |
Dietary choline and folate relationships with serum hepatic inflammatory injury markers in Taiwanese adults
|
Cheng C.-P.; CHIEN-HUNG CHEN; Kuo C.-S.; Kuo H.-T.; Huang K.-T.; Shen Y.-L.; Chang C.-H.; Huang R.-F.S. |
| 臺大學術典藏 |
2022-02-22T05:34:16Z |
Abdominoscrotal hydrocele
|
Liu K.-L.; Shih I.-L.; Huang Y.-C.; CHIEN-HUNG CHEN |
| 臺大學術典藏 |
2022-02-22T05:34:16Z |
Consensus development from the 5th asia-pacific primary liver cancer expert meeting (APPLE 2014)
|
Hsu C.; Chen B.-B.; CHIEN-HUNG CHEN; Ho M.-C.; Cheng J.C.-H.; Kokudo N.; Murakami T.; Yeo W.; Seong J.; Jia J.-D.; Han K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-02-22T05:34:16Z |
The role of age in change in unmet supportive care needs in hepatocellular carcinoma patients during transition from hospital to home
|
Shun S.-C.; Lai Y.-H.; Hung H.; CHIEN-HUNG CHEN; Liang J.-D.; Chou Y.-J. |
| 臺大學術典藏 |
2022-02-22T05:34:17Z |
Hepatitis B and C viruses are not risks for pancreatic adenocarcinoma
|
Chang M.-C.; CHIEN-HUNG CHEN; Liang J.-D.; Tien Y.-W.; Hsu C.; Wong J.-M.; Chang Y.-T. |
| 臺大學術典藏 |
2022-02-22T05:34:17Z |
Up-regulation of MicroRNA-190b plays a role for decreased IGF-1 that induces insulin resistance in human hepatocellular carcinoma
|
Hung T.-M.; Ho C.-M.; Liu Y.-C.; Lee J.-L.; Liao Y.-R.; Wu Y.-M.; Ho M.-C.; CHIEN-HUNG CHEN; Lai H.-S.; Lee P.-H. |
| 臺大學術典藏 |
2022-02-22T05:34:17Z |
Interrelationships among genetic C677T polymorphism of 5,10-methylenetetrahydrofolate reductase, biochemical folate status, and lymphocytic p53 oxidative damage in association with tumor malignancy and survivals of patients with hepatocellular carcinoma
|
Kuo C.-S.; Huang C.-Y.; Kuo H.-T.; Cheng C.-P.; CHIEN-HUNG CHEN; Lu C.-L.; Yang F.-L.; Syu Huang R.-F. |
| 臺大學術典藏 |
2022-02-22T05:34:18Z |
Autoantibody recognition of an N-terminal epitope of hnRNP L marks the risk for developing HBV-related hepatocellular carcinoma
|
Yau W.-Y.; Shih H.-C.; Tsai M.-H.; Sheu J.-C.; CHIEN-HUNG CHEN; Chow L.-P. |
| 臺大學術典藏 |
2022-02-22T05:34:18Z |
Elevated preoperative serum ca19-9 levels in patients with hepatocellular carcinoma is associated with poor prognosis after resection
|
Chen Y.-L.; CHIEN-HUNG CHEN; Hu R.-H.; Ho M.-C.; Jeng Y.-M. |
| 臺大學術典藏 |
2022-02-22T05:34:18Z |
Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies
|
Chen B.-B.; Shih I.-L.; Wu C.-H.; Hsu C.; CHIEN-HUNG CHEN; Shih T.T.-F.; Liu K.-L.; Liang P.-C. |
| 臺大學術典藏 |
2022-02-22T05:34:19Z |
Validating and improving the reliability of the EORTC QLQ-C30 using a multidimensional rasch model
|
Shih C.-L.; CHIEN-HUNG CHEN; Sheu C.-F.; Lang H.-C.; Hsieh C.-L. |
| 臺大學術典藏 |
2022-02-22T05:34:19Z |
Influence of Non-Alcoholic Fatty Liver Disease on Autonomic Changes Evaluated by the Time Domain, Frequency Domain, and Symbolic Dynamics of Heart Rate Variability
|
Liu Y.-C.; Hung C.-S.; Wu Y.-W.; Lee Y.-C.; Lin Y.-H.; Lin C.; Lo M.-T.; Chan C.-C.; Ma H.-P.; Ho Y.-L.; CHIEN-HUNG CHEN |
| 臺大學術典藏 |
2022-02-22T05:34:20Z |
Tumor lysis syndrome after transarterial chemoembolization plus portal venous embolization for hepatocellular carcinoma
|
Tsai W.-L.; Liang P.-C.; CHIEN-HUNG CHEN |
